Combination immunotherapy improves treatment response for head and neck cancer

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.

Asklepios shows resilience in 2023 financial year – Biotech Investments

EQS-News: Asklepios Kliniken / Key word(s): Annual Report Asklepios Group: Asklepios shows resilience in 2023 financial year 25.04.2024 / 10:00 CET/CEST The issuer is solely

April 26, 2024

Take Command Secures $25M to Expand ICHRAs Coverage

What You Should Know: – Take Command, a Dallas-based SaaS platform and employer-sponsored, personalized health benefits space secures $25M in growth stage financing led by

September 21, 2023

Poll: Majority of Brits fear cancer diagnosis more than any other condition

Two-thirds of the public say they are very or somewhat worried about being told they have the disease – higher than for any other medical

July 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.